Bluebird Bio Inc. (NASDAQ:BLUE)’s share price traded down 4.6% during mid-day trading on Monday . The company traded as low as $55.14 and last traded at $55.14, with a volume of 612,811 shares changing hands. The stock had previously closed at $57.80.

A number of equities analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Maxim Group restated a “buy” rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Zacks Investment Research upgraded shares of Bluebird Bio from a “sell” rating to a “hold” rating in a research report on Monday. Leerink Swann restated an “outperform” rating and set a $67.00 price objective on shares of Bluebird Bio in a research report on Thursday, August 4th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $149.00 price objective on shares of Bluebird Bio in a research report on Monday, April 11th. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $94.84.

The stock has a 50 day moving average price of $48.10 and a 200-day moving average price of $46.04. The company’s market capitalization is $2.06 billion.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. During the same period last year, the firm posted ($1.57) EPS. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. On average, equities research analysts anticipate that Bluebird Bio Inc. will post ($5.98) EPS for the current fiscal year.

In other news, insider Eric Sullivan sold 2,912 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total transaction of $160,189.12. Following the completion of the transaction, the insider now directly owns 4,456 shares in the company, valued at approximately $245,124.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Davidson sold 1,000 shares of the business’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $38.73, for a total value of $38,730.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $410,538. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of the company. New York State Common Retirement Fund raised its position in Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock valued at $10,983,000 after buying an additional 37,178 shares during the last quarter. Rhumbline Advisers raised its position in Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock valued at $2,303,000 after buying an additional 2,023 shares during the last quarter. Marshall Wace LLP raised its position in Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock valued at $10,816,000 after buying an additional 132,956 shares during the last quarter. California Public Employees Retirement System raised its position in Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock valued at $6,062,000 after buying an additional 57,700 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock valued at $55,506,000 after buying an additional 545,727 shares during the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.